OliX Diversifies Into mRNA Amid Growing Global Interest
Vaccines Thrust Tech Into Spotlight
Amid the highly successful launch of COVID-19 vaccines using the technology by Pfizer/BioNTech and Moderna, South Korean bioventure OliX Pharmaceuticals is diversifying into the mRNA field by establishing a new subsidiary that focuses on R&D into new vaccines and therapeutics using the platform.
You may also be interested in...
Falling foreign investment and increasing business uncertainties in China could present new opportunities for the Korean biopharma sector, which is stepping up globalization and R&D efforts to seek growth.
At a recent forum in Seoul, SK Group unveiled its biotech investment strategy and noted the next few years could present multiple major opportunities for Korean biotechs.
A recent forum in South Korea heard from a venture capital executive about the changing IPO and financing environment and how bioventures might be able to cope with these changes.